


Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006


This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

1. (Currently Amended) A compound having the formula:




where  $Y_1$  and  $Y_2$ , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, where X may be an alkyl, hydrogen, hydroxy-protecting group, hydroxyalkyl, alkoxyalkyl and aryloxyalkyl, and where the group R is represented by the structure:




where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, -OY, -CH<sub>2</sub>OY, -C≡CY and -CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, -COR<sup>5</sup> and a radical of the structure:

Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006




where m and n, independently, represent the integers from 0 to 5, where R<sup>1</sup> is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C<sub>1-5</sub>-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup>, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C<sub>1-5</sub> alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R<sup>1</sup> and R<sup>2</sup>, taken together, represent an oxo group, or an alkylidene group, =CR<sup>2</sup>R<sup>3</sup>, or the group -(CH<sub>2</sub>)<sub>p</sub>-, where p is an integer from 2 to 5, and where R<sup>3</sup> and R<sup>4</sup>, taken together, represent an oxo group, or the group -(CH<sub>2</sub>)<sub>q</sub>-, where q is an integer from 2 to 5, and where R<sup>5</sup> represents hydrogen, hydroxy, protected hydroxy, or C<sub>1-5</sub> alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups -CH(CH<sub>3</sub>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-, or -(CR<sub>1</sub>R<sub>2</sub>)- at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

2. (Original) The compound of claim 1 where R is a side chain of the formula




Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006


3. (Original) The compound of claim 1 where R is a side chain of the formula




4. (Original) The compound of claim 1 where R is a side chain of the formula



5. (Original) The compound of claim 1 where R is a side chain of the formula




6. (Original) The compound of claim 1 where R is a side chain of the formula




7. (Original) The compound of claim 1 where R is a side chain of the formula


Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006



8. (Original) The compound of claim 1 where R is a side chain of the formula




9. (Original) The compound of claim 1 where R is a side chain of the formula




10. (Original) The compound of claim 1 where R is a side chain of the formula

Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006



11. (Original) The compound of claim 1 where R is a side chain of the formula



12-16. (Canceled)

17. (Original) A pharmaceutical composition containing an effective amount of at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.

18. (Original) The pharmaceutical composition of claim 17 wherein said effective amount comprises from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of composition.

19. (Canceled)

20. (Original) The pharmaceutical composition of claim 17 containing 2-[(3'-methoxymethoxy)propylidene]-19-nor-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g.

Appln. No. 10/544,163  
Amdt. Dated March 14, 2007  
Reply to Office Action of December 16, 2006

21. (Canceled)
22. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (E-isomer) in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g.
23. (Canceled)
24. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (Z-isomer) in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g.
25. (Canceled)
26. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (E-isomer) in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g.
27. (Canceled)
28. (Original) The pharmaceutical composition of claim 17 containing 2-(3'-hydroxypropylidene)-19-nor-(20S)-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (Z-isomer) in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g.
- 29-109. (Canceled)